A carregar...
Do companies in the pharmaceutical supply chain earn excess returns?
Rising drug spending has led to increased calls to curtail drug costs. However, it is unclear where to target policy solutions. We estimated excess returns (the extent to which a firm’s profits are higher than expected given the risk associated with their investments) for manufacturers and middlemen...
Na minha lista:
| Publicado no: | Int J Health Econ Manag |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer US
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7780918/ https://ncbi.nlm.nih.gov/pubmed/33394339 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10754-020-09291-1 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|